Copy
RoverMed launches and announces its team
View this email in your browser

Greetings and Happy New Year!

I am very pleased to send you this first update of the year today to announce that RoverMed BioSciences, LLC has been launched and has announced our new team!

RoverMed BioSciences was founded by the leadership team at RNA and DNA-based therapeutics developer and recent Tekne Award recipient, GeneSegues Therapeutics, which was founded in 1999 by Dr. Gretchen Unger. RoverMed BioSciences was created in order to focus exclusively on advancing its industry leading crystallized ultra-small particle (CUSP) nanocapsule technology which is uniquely capable of delivering virtually any biologic drug directly into the nucleus of diseased cells -- no matter where they are in the body.  

RoverMed BioSciences will utilize a revenue driving business-to-business approach through engaging with partner pharmaceutical and bio-tech companies in order to enable efficient delivery for drugs highly dependent upon a precision targeted delivery system.  Essentially, due to the unique capabilities of our delivery technology, we have the potential to enable an entire class of new biologic drugs that could provide better outcomes for patients with challenging diseases with more efficacy and less toxicity.

The Press Release we issued at the launch highlights RoverMed’s Leadership Team:

Laura Brod, Chief Executive Officer -- Laura has served as the CEO of GeneSegues Therapeutics for the last two years and has led the strategy to seek and build partner relationships and improved leverage of the company’s core technology leading to the creation of RoverMed BioSciences.  She is a start-up business veteran and also serves as a member of the University of Minnesota Board of Regents and previously served in the Minnesota House of Representatives. Laura has previously been honored as one of the Mpls/St. Paul Business Journal's 40 under 40.

 Gretchen Unger, Ph.D., Chief Scientific Officer -- Dr. Unger is the founder of GeneSegues and inventor of the CUSP nanocapsule technology.  She has 25+ years in the industry and is known to be a leading expert in targeted nanoparticle sciences and lipid raft-mediated cell delivery.  Dr. Unger also has additional expertise in managing industrial scale-up processes important in nanotechnology. Dr. Unger has been part of over 18 successful federal grant applications of over $8MM dollars and over 20 related papers by Dr. Unger and her collaborators. 

Clay Anderson, Chief Financial Officer -- Clay is a highly experienced pharmaceutical executive having served as co-founder and CFO for multiple life science companies including Travanti Pharma, Verde Technologies and Vail Scientific.

Needless to say, we’re thrilled about the launch of RoverMed BioSciences and extremely excited about the future of this company and the potential impact of our technology.

Stay tuned for the next update which will highlight our experienced Board of Directors. 

Onward,

Laura



For more information visit www.RoverMed.com


 

Copyright © 2017 RoverMed, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp